{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T15:53:00Z","timestamp":1696348380262},"reference-count":16,"publisher":"Spandidos Publications","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.3892\/ol.2012.724","type":"journal-article","created":{"date-parts":[[2012,5,21]],"date-time":"2012-05-21T13:22:05Z","timestamp":1337606525000},"page":"262-264","source":"Crossref","is-referenced-by-count":3,"title":["Bortezomib-based treatment for relapsed and refractory angioimmunoblastic T-cell lymphoma: Case report and literature review"],"prefix":"10.3892","volume":"4","author":[{"given":"SHUYAN","family":"LIU","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ZHENGANG","family":"YUAN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"CHUNYANG","family":"ZHANG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"WEIJUN","family":"FU","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JIAN","family":"HOU","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2012,5,21]]},"reference":[{"key":"key20180108092126_b1-ol-04-02-0262","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"key":"key20180108092126_b2-ol-04-02-0262","doi-asserted-by":"crossref","first-page":"4463","DOI":"10.1182\/blood-2007-08-105759","article-title":"Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte (GELA) trials","volume":"111","author":"Mourad","year":"2008","journal-title":"Blood"},{"key":"key20180108092126_b3-ol-04-02-0262","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/j.1365-2141.2009.08003.x","article-title":"Advances in the understanding and management of angioimmunoblastic T-cell lymphoma","volume":"148","author":"de Leval","year":"2010","journal-title":"Br J Haematol"},{"key":"key20180108092126_b4-ol-04-02-0262","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1182\/blood-2007-02-074641","article-title":"Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial","volume":"110","author":"Gallamini","year":"2007","journal-title":"Blood"},{"key":"key20180108092126_b5-ol-04-02-0262","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1365-2141.2010.08298.x","article-title":"Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma","volume":"150","author":"d\u2019Amore","year":"2010","journal-title":"Br J Haematol"},{"key":"key20180108092126_b6-ol-04-02-0262","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1365-2141.2006.06457.x","article-title":"Phase II trial of denileukin diftitox for relapsed\/refractory T-cell non-Hodgkin lymphoma","volume":"136","author":"Dang","year":"2007","journal-title":"Br J Haematol"},{"key":"key20180108092126_b7-ol-04-02-0262","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study","volume":"29","author":"O\u2019Connor","year":"2011","journal-title":"J Clin Oncol"},{"key":"key20180108092126_b8-ol-04-02-0262","doi-asserted-by":"crossref","first-page":"5827","DOI":"10.1182\/blood-2010-10-312603","article-title":"Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma","volume":"117","author":"Piekarz","year":"2011","journal-title":"Blood"},{"key":"key20180108092126_b9-ol-04-02-0262","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1080\/10428190601137658","article-title":"Angioimmunoblastic T cell lymphoma: treatment experience with cyclosporine","volume":"48","author":"Advani","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"key20180108092126_b10-ol-04-02-0262","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1080\/10428190802233165","article-title":"Complete remission induced by thalidomide in a case of angioimmunoblastic T-cell lymphoma refractory to autologous stem cell transplantation","volume":"49","author":"Gottardi","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"key20180108092126_b11-ol-04-02-0262","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3324\/haematol.10737","article-title":"Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience","volume":"92","author":"Arkenau","year":"2007","journal-title":"Haematologica"},{"key":"key20180108092126_b12-ol-04-02-0262","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1093\/annonc\/mdn431","article-title":"Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK\/T-cell lymphoma","volume":"19","author":"Lee","year":"2008","journal-title":"Ann Oncol"},{"key":"key20180108092126_b13-ol-04-02-0262","first-page":"1419","article-title":"Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma","volume":"7","author":"Sunwoo","year":"2001","journal-title":"Clin Cancer Res"},{"key":"key20180108092126_b14-ol-04-02-0262","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1182\/blood-2007-08-108654","article-title":"PRDM1 is involved in chemoresistance of T-cell lymphoma and down-regulated by the proteasome inhibitor","volume":"111","author":"Zhao","year":"2008","journal-title":"Blood"},{"key":"key20180108092126_b15-ol-04-02-0262","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00277-010-1022-1","article-title":"Proteasome inhibitor bortezomib targeted tumor-endothelial cell interaction in T-cell leukemia\/lymphoma","volume":"90","author":"Shi","year":"2011","journal-title":"Ann Hematol"},{"key":"key20180108092126_b16-ol-04-02-0262","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1038\/sj.leu.2403960","article-title":"Differential expression of NF-kappaB pathway genes among peripheral T-cell lymphomas","volume":"19","author":"Mart\u00ednez-Delgado","year":"2005","journal-title":"Leukemia"}],"container-title":["Oncology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/ol.2012.724\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,8]],"date-time":"2018-01-08T10:17:55Z","timestamp":1515406675000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/ol.2012.724"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,21]]},"references-count":16,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2012,5,21]]},"published-print":{"date-parts":[[2012,8]]}},"alternative-id":["10.3892\/ol.2012.724"],"URL":"https:\/\/doi.org\/10.3892\/ol.2012.724","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,21]]}}}